4.8 Article

Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy

Publisher

NATL ACAD SCIENCES
DOI: 10.1073/pnas.1909649117

Keywords

facioscapulohumeral muscular dystrophy; DUX4; LNA gapmers; antisense therapy; FLExDUX4 mouse model

Funding

  1. FSH Society
  2. Muscular Dystrophy Canada
  3. University of Alberta
  4. Women and Children's Health Research Institute
  5. Friends of FSH Research
  6. FSHD Global Research Foundation
  7. Friends of Garrett Cumming Research Fund
  8. HM Toupin Neurological Science Research Fund
  9. Canadian Institutes of Health Research
  10. Canada Foundation for Innovation
  11. Alberta Enterprise and Advanced Education

Ask authors/readers for more resources

Facioscapulohumeral muscular dystrophy (FSHD), characterized by progressive muscle weakness and deterioration, is genetically linked to aberrant expression of DUX4 in muscle. DUX4, in its full-length form, is cytotoxic in nongermline tissues. Here, we designed locked nucleic acid (LNA) gapmer antisense oligonucleo-tides (AOs) to knock down DUX4 in immortalized FSHD myoblasts and the FLExDUX4 FSHD mouse model. Using a screening method capable of reliably evaluating the knockdown efficiency of LNA gapmers against endogenous DUX4 messenger RNA in vitro, we demonstrate that several designed LNA gapmers selectively and effectively reduced DUX4 expression with nearly complete knock-down. We also found potential functional benefits of AOs on mus-cle fusion and structure in vitro. Finally, we show that one of the LNA gapmers was taken up and induced effective silencing of DUX4 upon local treatment in vivo. The LNA gapmers developed here will help facilitate the development of FSHD therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available